News

Published on 8 Apr 2024 on Zacks via Yahoo Finance

How Allogene (ALLO) Stock Stands Out in a Strong Industry


Article preview image

One stock that might be an intriguing choice for investors right now is Allogene Therapeutics, Inc. ALLO. This is because this security in the Medical - Biomedical and Genetics space is seeing solid earnings estimate revision activity, and is in great company from a Zacks Industry Rank perspective.

This is important because, often times, a rising tide will lift all boats in an industry, as there can be broad trends taking place in a segment that are boosting securities across the board. This is arguably taking place in the Medical - Biomedical and Genetics space as it currently has a Zacks Industry Rank of 73 out of more than 250 industries, suggesting it is well-positioned from this perspective, especially when compared to other segments out there.

Meanwhile, Allogene is actually looking pretty good on its own too. The firm has seen solid earnings estimate revision activity over the past month, suggesting analysts are becoming a bit more bullish on the firm’s prospects in both the short and long term.

NASDAQ.ALLO price evolution

Want to become a better investor?

Start tracking your investments with Statfolio

Sign up for free
Related News
Allogene Therapeutics Inc (ALLO) Q3 2024 Earnings Call Highlights: Financial...

Allogene Therapeutics Inc (ALLO) reports a strong cash position and promising clinical progress,...

GuruFocus.com · via Yahoo Finance 8 Nov 2024

Allogene Therapeutics Inc (ALLO) Q3 2024: Everything You Need To Know Ahead Of...

Allogene Therapeutics Inc (NASDAQ:ALLO) is set to release its Q3 2024 earnings on Nov 7, 2024. Th...

GuruFocus.com · via Yahoo Finance 6 Nov 2024

Allogene Therapeutics, Inc. (ALLO): Among the Rising Penny Stocks to Invest In...

We recently compiled a list of the 7 Best Rising Penny Stocks To Invest In Now. In this article, ...

Insider Monkey · via Yahoo Finance 6 Oct 2024

Allogene Therapeutics, Inc. (ALLO): Short Seller Sentiment is Bearish on This...

We recently compiled a list of the 10 Worst Cancer Stocks To Buy Now According to Short Sellers. ...

Insider Monkey · via Yahoo Finance 19 Sep 2024

With 56% institutional ownership, Allogene Therapeutics, Inc. (NASDAQ:ALLO) is a...

Key Insights Significantly high institutional ownership implies Allogene Therapeutics' stock pric...

Simply Wall St. · via Yahoo Finance 18 Jun 2024

Allogene Therapeutics, Inc. (ALLO): Are Analysts Bullish About the Potential of...

We recently compiled a list of the Top 10 Small-Cap Stocks with Highest Upside Potential. In this...

Insider Monkey · via Yahoo Finance 18 Jun 2024

How Allogene (ALLO) Stock Stands Out in a Strong Industry

One stock that might be an intriguing choice for investors right now is Allogene Therapeutics, In...

Zacks via Yahoo Finance 8 Apr 2024

Allogene Therapeutics, Inc. (NASDAQ:ALLO) Q4 2023 Earnings Call Transcript

Allogene Therapeutics, Inc. (NASDAQ:ALLO) Q4 2023 Earnings Call Transcript March 14, 2024 Allogen...

Insider Monkey via Yahoo Finance 16 Mar 2024

Allogene's (ALLO) Q4 Loss Narrower Than Expected, Sales Miss

Allogene Therapeutics, Inc. ALLO incurred an adjusted loss (excluding impairment of long-lived as...

Zacks via Yahoo Finance 15 Mar 2024

Allogene licenses CRISPR tech for autoimmune treatment

This collaboration aims to advance the development of treatments for autoimmune diseases using...

Investing.com 11 Mar 2024